Over 29 million people living in the United States have Type II diabetes (DMT2). One of the most frequent complications of this disease is chronic constipation, in some cases caused by nerve damage in the wall of the intestines, which slows down the ability to digest and eliminate waste. Unfortunately, for many suffering with severe symptoms, over-the-counter medications or currently available prescription medications do not work. But relief may be on its way.
Irene Sarosiek, M.D., associate professor of medicine and director of GI motility and neurostimulation research in the Texas Tech University Health Sciences Center (TTUHSC) El Paso Department of Internal Medicine, is the author and principal investigator on a study entitled “Efficacy of Linaclotide in Diabetics with Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial”, which has been funded in the amount of $100,298 by Forest Research Institute, Inc. Richard W. McCallum, M.D., professor in the Division of Gastroenterology, Tamis Bright, M.D., assistant professor and chief in the Division of Endocrinology, and Jerzy Sarosiek, M.D., Ph.D., professor of medicine, associate chairman of research, Department of Internal Medicine, serve as co-investigators and clinicians on this project. “This study is designed for diabetic patients who suffer from severe constipation and have had no adequate relief of symptoms using their current medications,” said Dr. Sarosiek. “We anticipate learning if this FDA approved drug – Linaclotide – will successfully alleviate their symptoms when compared with a placebo.”
“Linaclotide has been proven to effectively treat chronic constipation in non-diabetic patients,” said Dr. Sarosiek. “We hope to see the same clinical outcome with DMT2 patients – positively impacting the quality of life for many diabetic patients diagnosed with chronic constipation.
To enroll in this study or find out further information, contact Yvette Gomez, lead study coordinator, at (915) 215-5189.